Analysis of myopathy in a placebo-controlled zidovudine trial

Muscle and Nerve

Volumn 20, Issue 3, 1997, Pages 382-385

  Simpson, David M ^a   Slasor, Peter ^b   Dafni, Urania ^b   Berger, Joseph ^c   Fischl, Margaret A ^c   Hall, Colin ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

elevated creatine kinase; HIV 1; Myopathy

Indexed keywords

CREATINE KINASE; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MYALGIA; MYOPATHY; MYOSITIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CREATINE KINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MUSCULAR DISEASES; PLACEBOS; ZIDOVUDINE;

EID: 0031035495     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4598(199703)20:3<382::AID-MUS22>3.0.CO;2-1     Document Type: Article

References (11)

1. Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, Schon EA: Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991;337:508-510.
2. Berman A, Espinoza LR, Diaz JD, Aguilar JL, Rolando T, Vasey FB, Germain BF, Lockey RF: Rheumatic manifestation of human immunodeficiency virus infection. Am J Med 1988;85:59-64.
3. Bessen LJ, Greene JB, Louie E, Seitzman P, Weinberg H: Severe polymyositis-like syndrome associated with zidovudine therapy of AIDS and ARC. N Engl J Med 1988;2:318:708.
4. Chariot P, Monnet I, Gherardi R: Cytochrome C oxidase reaction improves histopathological assessment of zidovudine myopathy. Ann Neurol 1993;34:561-565.
5. Cupler EJ, Hench K, Jay CA, Grady C, Danon MJ, Ropka M, Dalakas M: The natural history of zidovudine (AZT)-induced mitochondrial myopathy [abstract]. Neurology 1994(suppl 2);44:A132.
6. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL: Mitochondrial myopathy caused by long-term zidovudine therapy in AIDS. N Engl J Med 1990;322:1098-1105.
7. Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, Hardy WD, Dolin R, Powderly WG, Allan JD, Wong B, Merigan TC, McAuliffe VJ, Hyslop NY, Rhame FS, Balfour HH, Spector SA, Volberding P, Pettinelli C, Anderson J: The safety and efficacy of zidovudine (AZT) in the treatment of patients with mildly symptomatic HIV infection: a double-blind, placebo-controlled trial. Ann Intern Med 1990;112:727-737.
8. Gonzales MF, Olney RK, So YT, Greco CM, McQuinn BA, Miller RG, DeArmond SJ: Subacute structural myopathy associated with human immunodeficiency virus infection. Arch Neurol 1988;45:585-587.
9. Grau JM, Masanes F, Pedreo E, Casedemont J, Fernandez-Sola J, Urbano-Marquez A: Human immunodeficiency virus type 1 infection and myopathy: clinical relevance of zidovudine therapy. Ann Neurol 1993;34:206-211.
10. Herzberg NH, Zorn I, Zwart R, Portegies P, Bolhuis PA: Major growth reduction and minor decrease in mitochondrial enzyme activity in cultured human muscle cells after exposure to zidovudine. Muscle Nerve 1992;15:706-710.
11. Manji H, Harrison MJG, Round JM, Jones DA, Conolly S, Fowler CJ, Williams I, Weller IVD: Muscle disease, HIV and zidovudine: the spectrum of muscle disease in HIV-infected individuals treated with zidovudine. J Neurol 1993;240:-479-488.